Older pharmacologic therapy for nocturnal enuresis
Related Experiment Video
Updated: Aug 17, 2026

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
Published on: August 9, 2012
1Department of Pediatric Urology, Children's National Medical Center, Washington, D.C. 20010.
Abstract:
Since the early 1960s, a number of pharmacologic agents have been used to treat children with enuresis. Success has been reported with tricyclic antidepressants (imipramine), anticholinergics (oxybutynin), and desmopressin acetate (DDAVP). Sedatives, stimulants, or sympathomimetic agents have not proved beneficial. Because treatment with medication may be effective even in children with an organic problem such as infection or neuropathy, patients should always be evaluated carefully before drug therapy is started. Of the tricyclic antidepressants, imipramine has been investigated and used the most extensively. Oxybutynin is beneficial for children with small bladder capacity and daytime enuresis. DDAVP, introduced in the 1990s, has response rates similar to those of imipramine but with fewer side effects.
More Related Videos
10:07Cystometric and External Urethral Sphincter Measurements in Awake Rats with Implanted Catheter and Electrodes Allowing for Repeated Measurements
Published on: January 30, 2018
04:53Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Published on: October 18, 2024
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Management of Insomnia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care